A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma.

Trial Profile

A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jan 2013 Planned end date changed from 1 Oct 2007 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Status changed from suspended to recruiting. as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top